{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-010154","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2023-05-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.556877+00:00","generated_at":"2026-06-14T20:37:07.203662+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Protalix receives $20M milestone from Chiesi after FDA approval of ELFABRIO","bullets":["$20M milestone triggered by FDA approval of ELFABRIO (pegunigalsidase alfa-iwxj) for Fabry disease; payable within 30 days.","Proforma cash position including milestone is $51.6M as of May 18, 2023.","Protalix has received $95M total in upfront and development cost payments from Chiesi under two agreements.","Eligible for up to $1.0B in future regulatory and commercial milestones plus tiered royalties (15-40% US, 15-35% ex-US).","CEO Dror Bashan states the payment strengthens financial position; partner Chiesi has global commercial expertise."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-010154","json":"https://secwatch.observer/filing/0001558370-23-010154.json","markdown":"https://secwatch.observer/filing/0001558370-23-010154.md","text":"https://secwatch.observer/filing/0001558370-23-010154.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023010154/0001558370-23-010154-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000155837023010154/plx-20230518x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T20:37:07.203662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}